Vibrating mattress helps clear Alzheimer’s protein from the brain

Scientists at King's College London have discovered a potential new treatment for Alzheimer's disease that addresses multiple aspects of the condition simultaneously. The experimental drug, KCL-286, originally developed for spinal cord injuries, shows promise in repairing damaged DNA, reducing inflammation, and targeting other biological processes associated with Alzheimer's.

Unlike treatments that primarily target toxic protein buildup, KCL-286 tackles processes that may begin earlier in the disease's progression. An advantage of KCL-286 is that it has already completed Phase 1 human safety trials, potentially accelerating its progression through clinical testing. The drug, which is taken orally, could offer a more convenient treatment option compared to those requiring injections or infusions.

Alzheimer's disease is difficult to treat due to its complex nature, involving the accumulation of abnormal proteins and other brain changes. While medications targeting amyloid-beta and tau proteins have shown some benefits, they do not fully address the disease's many underlying processes. Researchers are now exploring other targets, such as DNA damage and brain inflammation, which can appear early in the disease.

KCL-286 works by activating a protein involved in the retinoic acid pathway, which is linked to vitamin A processing. This activation may help repair DNA damage and reduce inflammation in Alzheimer's-affected brains. Early research suggests that KCL-286 could serve as a disease-modifying therapy, potentially slowing the progression of Alzheimer's by targeting multiple harmful processes simultaneously.